期刊文献+

氢吗啡酮预防全麻腹腔镜手术苏醒期躁动的效果 被引量:11

下载PDF
导出
摘要 苏醒期躁动是全麻术后最常见的并发症之一,导致苏醒期躁动的因素很多,疼痛刺激、全麻药残留是最主要的原因。腹腔镜手术由于手术时间短,CO2气腹等因素的影响导致苏醒期躁动发生率比其他手术明显增多。氢吗啡酮是一种新型的阿片类镇痛药,由于其起效时间快、镇痛作用强、持续时间长、副作用很轻微,适用于术后急性疼痛治疗。
出处 《实用临床医药杂志》 CAS 2014年第21期144-145,共2页 Journal of Clinical Medicine in Practice
  • 相关文献

参考文献9

  • 1隋平,阮辉.全麻术后躁动原因分析[J].中国医学创新,2011,8(3):34-35. 被引量:10
  • 2Wills V L,Hunt D R.Pain after laparroscopic cholecysteetomy[J].Br JSurg,2000,87(3):273.
  • 3Zhao M,Joo D T.Enhancement of spinal N-methyl-D-aspartate receptor function by remifentanil action at 8-opioid receptors as a mechanism for acute opioid-induced hyperalgesia or tolerance[J].Anesthesiology,2008,109(2):308.
  • 4Bonica J J.Fundamentalconsiderations of chronicpain therapy[J].Postgrad Med,1993,53:81.
  • 5Harvey R,Champe P.Opioid analgesics and antagonists[M].Lippincott:Philadelphia,992:133.
  • 6Ritschel W A,Parab P V,Denson D D,et al.Absolute bioavailability of hydromorphone after peroral and rectal administration in humans:saliva/plasma ratio and clinical effects[J].J Clin Pharmacol,1987,27:647.
  • 7Columba Quigley,M D,MRCP and Phil Wiffen,MRPharm S.A Systematic Review of Hydromorphone in Acute and Chronic Pain[J].Journal of Pain and Symptom Management,2003,25:169.
  • 8Eddy N B.Dihydromorphinone hydrochloride[J].JAMA,1933,100:1032.
  • 9Pigni A,Brunelli C,Caraceni A.The role of hydromorphone in cancer pain treatment:a systematic review[J].Palliat Med,2011,25(5):471.

二级参考文献4

共引文献9

同被引文献133

  • 1王永顺.布托啡诺治疗不同年龄小儿全身麻醉后苏醒期躁动的效果及安全性[J].中国医药导刊,2013,15(S1):140-141. 被引量:4
  • 2Felden L,Walter C,Harder S,et al.Comparative clinical effects of hydro- morphone and morphine:a meta-analysis[J].BrJ Anaesth,2011,107(3):319-328.
  • 3Chang AK,Bijur PE,Baccelieri A,et al.Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute,severe pain:a prospective,randomized,double-blind clinical trial[J].AmJ Geriatr Pharmacother,2009,7(1):1-10.
  • 4Kumar P,Sunkaraneni S,Sirohi S,et al.Hydromorphone efficacy and treat- ment protocol impact on tolerance and mu-opioid receptor regulation[J]. Eur J Pharmacol,2008,597(1/2/3):39-45.
  • 5Turgeon J,G,Qning R,Sathyan G,et al.The pharmacokinetics of a long- acting OROS hydromorphone formulation[J].Expert Opin Drug Deliv,2010,7(1):137-144.
  • 6Jeleazcov C,Saari TI,Ihmsen H,et al.Population pharmacokinetic mo- deling of hydromorphone in cardiac surgery patients during postoperative pain therapy[J].Anesthesiology,2014,120(2):378-391.
  • 7Abrishamkar S,Eshraghi N,Feizi A,et al.Analgesic effects of ketamine infusion on postoperative pain after fusion and instrumentation of the lumbar spine:a prospective randomized clinical trial[J].Med Arh,2012,66(2):107-110.
  • 8Lee SH,Lee CJ,Kim TH,et al.Novel Use of Hydromorphone as a Pretreat- ment Agent:A Double-blind,Randomized,Controlled Study in Adult Korean Surgical Patients[J].Curr Ther Res Clin Exp,2011,72(1):36-48.
  • 9Chang AK,Bijur PE,Napolitano A,et al.Two milligrams i.v.hydromor- phone is efficacious for treating pain but is associated with oxygen desatu- ration[J].J Opioid Manag,2009,5(2):75-80.
  • 10Chang AK,Bijur PE,Davitt M,et al.Randomized clinical trial comparing a patient-driven titration protocol of intravenous hydromorphone with tra- ditional physician-driven management of emergency department patients with acute severe pain[J],Ann Emerg Med,2009,54(4):561-567.

引证文献11

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部